We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca, Eli Lilly Push Back Against HHS’ 340B Drug Discount Deadline
AstraZeneca, Eli Lilly Push Back Against HHS’ 340B Drug Discount Deadline
Despite a recent warning from HHS that drugmakers could face fines if they continue to hold back 340B drug discounts from clinics and hospitals serving low-income patients, Eli Lilly and AstraZeneca (AZ) appear determined to resist, filing motions in federal court against the department’s June 1 deadline.